Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Phase 2

Recruiting

• Conditions: Breast Cancer; Radiotherapy Side Effect
• Interventions: Radiation: Ultra-fractionated radiation therapy

• Registration Number: NCT05762900
• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Brief Summary

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

Detailed Description

During the study, the patients would undergo radiation of 5.2Gy for 5 fractions to the prophylactic radiation volumes and and a 6Gy per-fraction simultaneous boost to the tumor bed or other high-risk volumes. Acute toxicity of grade 2 or higher in the following 12 weeks after radiotherapy is the primary end point.

Study Timeline

• Study Start: 2022-10-25
• Study First Submitted: 2023-02-20
• Status Verified: 2023-03
• Study First Submitted QC: 2023-03-09
• Last Update Submitted: 2023-03-09
• Study First Posted: 2023-03-10
• Last Update Posted: 2023-03-10
• Primary Completion: 2025-10-25
• Study Completion: 2030-10-25

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 65

Inclusion Criteria

1. Patients diagnosed with invasive or non-invasive breast cancer;
2. The patients have undergone breast-conserving surgery or mastectomy with axillary sentinel nodal biopsy or dissection;
3. Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery).
4. No distant metastasis;
5. Life expectancy ≥6 months;
6. Organ function is fine (Hemoglobin ≥100g/L, leukocyte ≥2×109/L, neutrophil ≥1×109/L, platelet ≥80×109/L; Creatinine 1.5 mg/dl or less; Alanine aminotransferase/aspartate aminotransferase ≤2.5×UNL.);
7. Patients are willing to cooperate to follow up;
8. Patients should sign the informed consent;
9. Women of childbearing age need effective contraception.

Exclusion Criteria

1. Biopsy proven ipsilateral supraclavicular, infraclavicular or internal mammary nodal involvement.
2. Concurrent or previous neuropathy overlapping with the radiation volume or brachial plexus injury;
3. Patients who had radiotherapy to the ipsilateral breast, lymph-drainage regions or adjacent areas before;
4. Concurrent active connective tissue disease;
5. Other malignancies, which affect patient life expectancy (except adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder neoplasms (no more than T1), early stage thyroid carcinoma);
6. Severe comorbidities or active disease (Poorly controlled heart disease: New York Classification of Cardiac Function ≥ Grade 2, active coronary heart disease, unstable angina pectoris, arrhythmia requiring medical treatment/persistent refractory hypertension; Myocardial infarction, stroke within six months; Poorly controlled diabetes persists. Fasting blood glucose ≥ 10mmol/L, 2 hours postprandial blood glucose ≥ 13 mmol/L. Poorly controlled psychosis develops or worsens within six months; Active infection; Positive for antibodies to HIV).
7. Pregnant or breast-feeding.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Ultra-hypofractionated arm	Ultra-fractionated radiation therapy	The patients will be treated by Ultra-hypofractionated irradiation.

Primary Outcome Measures

Name	Time	Method
The rate of patients who develop radiation-associated acute toxicity (≥ 2 degree)	until 12 weeks from the completion of postoperative radiotherapy	The investigators will record the incidence of ≥ 2 degree radiation-associated acute toxicity, such as breast or chest wall oedema, acute dermatitis, breast pain,itch of breast skin; ≥ 3 degree radiation-associated esophagitis; ≥ 3 degree radiation-associated lymphopenia.

Secondary Outcome Measures

Name	Time	Method
Local regional recurrence rate	Local regional recurrence rate would be recorded and reported until at least 5 years after diagnosis.	The incidence of recurrence in the ipsilateral breast/chest wall or the lymphatic nodal regions.
Disease-free survival	Until at least 5 years after diagnosis.	The time interval from diagnosis to any event of recurrence or death.
The cosmetic outcome.	The cosmetic outcome will be evaluated before and at 12, 24 and 60 months after radiotherapy.	Breast Cancer Treatment Outcome Scale 22 (brev: BCTOS 22) is used, for patients who receive breast conservative surgery. The higher the score, the worse the cosmesis, with the range of 22 to 88.
Local recurrence rate	Local recurrence rate would be recorded and reported until at least 5 years after diagnosis.	The incidence of recurrence of any invasive or non-invasive breast cancer in the ipsilateral breast or chest wall.
Overall survival	Until at least 5 years after diagnosis.	The time interval from diagnosis to death from any reason.
Quality of Life.	The patients' quality of life will be evaluated before and at 12, 24 and 60 months after radiotherapy.	European Organization for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life Questionnaire (brev: EORTC BR-23) is used. The higher the score, the worse the situation, with the range of 23 to 92.
The rate of patients who develop radiation-associated long-term toxicity	From 12 weeks to 5 years post radiotherapy.	The investigators will record the incidence of any long-term toxicities, such as skin or subcutaneous fibrosis, pain, breast distortion, brachial plexopathy, lymphodema, cardiac event, rib fracture, pulmonary fibrosis, and so on.

Trial Locations

Locations (1)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 🇨🇳 Beijing, China